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Drugs reviews 
Compiled by David Tibbutt MD 
1. Drugs and damage to the liver 
 
This short review was inspired by an article in "Hospital Medicine" 1. The availability of plasma liver function 
tests (LFTs) to monitor hepatotoxicity (liver [hepatic] damage) is uncommon in many resource-poor 
countries. Even so we must be aware of and not ignore the risk of hepatic damage from many commonly used 
drugs. It is important to realise that drugs are the commonest cause of liver failure. 
The likelihood (susceptibility) of an individual suffering the hepatotoxic effects of any chemical depends on 
many factors: 
 In children salicylates and valproic acid more commonly cause microvesicular steatosisa.  
 Older people are more at risk from isoniazid. 
 Females are more at risk of adverse drug reactions in the liver than males. 
 Nutrition influences the chance of hepatotoxicity. 
 Alcohol abuse: e.g. small amounts of paracetamol may cause liver damage. 
 Pregnancy. 
 Underlying liver disease: toxicity may not necessarily be more common but if a toxic effect does occur 
it is likely to be more serious because of the reduced liver reserve. 
 Genetic differences in enzymes (e.g. cytochrome p450) and immunity. 
There are two main mechanisms in the generation of a toxic effect; these may work separately or together: 
 An immune response (in which there may be a rash, fever and eosinophilia which should be fairly easily 
detected on a blood film) and/or 
 Interference with cellular biochemistry. 
A number of biochemical and clinical patterns of drug-induced hepatotoxicity may occur as shown in Table 1. 
 
Table 1. Patterns of drug/chemical hepatotoxicity 
Type Features Enzymes 
Acute hepatocellular 
damage (commonest) 
Hepatitis, necrosis, steatosis ALT = 2 x ULN 
or 
Ratio ALT : ALP > 5 
Acute cholestaticb damage Pruritus (itching), jaundice, pain, 
rash, fever 
ALP > 2 x ULN 
or 
Ratio ALT : ALP < 5 
Mixed  Ratio ALT : ALP = 2 - 5 
[ALT: alanine transaminase; ALP: alkaline phosphatase; ULN: upper limit of normal.] 
 
How do we conclude that a drug (or chemical) may be the cause of an hepatic problem? 
 Firstly consider the possibility - i.e. be very suspicious and remember the eight bullet points listed 
above. 
 If the patient has been on the drug for over 3 months the chance of toxicity is less likely. 
 Has the clinical/biochemical situation improved since the drug was withdrawn? 
 If the drug has been given more than once (not a wise thing to do!!) has the patient experienced the same 
toxic problem? 
                                                     
a 'Microvesicular steatosis of the liver' refers to a type of liver fat accumulation. It was originally described in 
association with conditions which share a limited number of similar features: acute fatty liver of pregnancy, Reye's 
syndrome, sodium valproate toxicity, high-dose tetracycline toxicity and certain congenital defects of urea cycle enzymes. 
Recently the disease has been described in many conditions: alcoholism, toxicity of several medications, delta hepatitis in 
South America and Central Africa, sudden childhood death, congenital defects of fatty acid beta oxidation and 
cholesterol ester storage disease. Our understanding of the pathogenesis of microvesicular steatosis is limited. In some 
cases it may be linked to a mitochondrial abnormality.  
 
b Conditions giving rise to cholestasis (i.e cholestatic situations) fall into two main categories. Those where there: 
 is a mechanical blockage in the duct system - obstructive or extrahepatic cholestasis. 
 are disturbances in bile formation - hepatocellular or intrahepatic cholestasis. 
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The problem with many patients is that they are taking several drugs often including herbal traditional 
remedies. 
Drugs that may cause hepatic problems 
 Sulphonylureas (e.g. glibenclamide, chlorpropamide) may cause an hepatitis with a cholestatic or 
granulomatousc pattern associated with hypersensitivity features of rash, fever, arthralgia and eosinophilia. 
In severe cases erythema multiforme and exfoliative dermatitis may occur. These reactions usually appear 
within the first eight weeks of treatment. 
 Chlorpromazine and prochlorperazine commonly cause cholestasis. 
 Phenytoin and carbamazepine may lead to the 'reactive metabolite syndrome'. This occurs up to eight 
weeks after taking the drug. The features are fever, rash, lymphadenopathy and often Stevens-Johnsons 
syndrome. There is frequently hepatocellular damage. 
 Erythromycin may lead to pruritus (itching), jaundice and a blood eosinophilia reflecting cholestatic 
toxicity. 
 Anti-tuberculous drugs cause LFT disturbance in 20% of patients but do not usually lead to clinical 
problems as the abnormalities resolve even as treatment is continued. Nevertheless hepatic toxicity can be 
serious and life-threatening. So beware! 
  
Rifampicin + isoniazid 
↓ 
Induction of p450 enzymes 
↓ 
Enhanced production of toxic metabolites 
from isoniazid 
↓ 
Serious hepatotoxicity in 1% 
(hepatocellular pattern) 
 
Similarly pyrazinamide causes hepatotoxicity. This is dose-related so reduce the dose for small patients. 
 
Advice for the treatment of tuberculosis  
Measure LFTs before treatment and if abnormal repeat every two to four weeks. If enzyme levels rise to more 
than five times the upper limit of normal withhold treatment until there is a return to baseline figures. 
 
 Anti-retroviral drugs (ARVs): many raise the liver enzymes (e.g. ritonavir, saquinavir) and some cause 
a severe hepatitis (e.g. nevirapine) which may be fatal, or hepatic steatosis (e.g. stavudine). As the 
availability of ARVs increases there will be a need to widen the facilities for LFTs. 
Herbal medicines 
Herbal and other 'traditional' remedies are used widely in Africa. However little has been published about their 
use or adverse effects. 
Reference 
1. Rashid M, Goldin R and Wright M. Drugs and the liver. Hospital Medicine 65 (8): 456 – 461. 2004 
 
 
2. Side-effects of drugs used to treat tuberculosis 
The review above stated that "Anti-tuberculous drugs cause Liver Function Test (LFT) disturbance in 20% 
of patients but uncommonly lead to clinical problems as the abnormalities resolve even as treatment is 
continued". However in a small number of patients severe hepatotoxicity may result. The more drugs that are 
prescribed to a patient at the same time the more likely there is to be an adverse reaction. The treatment of 
tuberculosis usually involves the use of four drugs in the initial phase. This review summarises the potential 
                                                     
c A granuloma is a roughly spherical mass of immune cells that forms when the immune system attempts to wall off 
substances that it perceives as foreign but is unable to eliminate. Such substances include infectious organisms such as 
bacteria and fungi as well as other materials such as keratin and suture fragments. A granuloma is a special type of 
inflammation that can occur in a wide variety of diseases. The adjective granulomatous means characterized by granulomas 
(from “Wikipedia”). 
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complications that rifampicin, isoniazid, pyrazinamide and ethambutol may cause. Thiacetazone is mentioned 
although it is much less commonly used. 
Potential complications 
Rifampicin 
 Gastro-intestinal symptoms are common with many drugs and often these will clear if the patient is able 
to tolerate them: anorexia, nausea, vomiting and diarrhoea.  
 Urine, saliva and other body fluids may be coloured orange-red: this can be very alarming to patients 
so they should be warned and reassured.  
 The hepatic microsomal enzymes are induced and these increase the rate of metabolism of certain 
medications such as oral contraceptives and antidiabetic drugs (sulphonylureas [e.g. glibenclamide, 
chlorpropamide] and biguanides [e.g. metformin]), steroids and dapsone. The effectiveness of these drugs 
is likely to be reduced. 
Side-effects are uncommon but include: 
 Skin reactions: rash, urticaria, flushing. Fortunately many of these reactions are self-limiting and 
gradually clear; the patient only needs symptomatic relief and reassurance until this happens. 
 Myalgia (muscle aches and weakness). 
 Hepatitis: see advice for patients under isoniazid. 
 Fever. 
 Thrombocytopaenia (reduced platelet numbers so predisposing the patient to bleeding) and rarely 
haemolytic anaemia, leucopaenia (low white blood cell count predisposing the patient to infection) 
and eosinophilia. 
Isoniazid 
 Gastro-intestinal symptoms: nausea, vomiting. 
Most serious side-effects are uncommon (except peripheral neuropathy). There are two groups of patients: 
slow and fast acetylators. The fast acetylators metabolise isoniazid more rapidly than the slow acetylators. 
Therefore the slow acetylators are more likely to experience adverse reactions. 
 Peripheral neuropathy is more common in patients with diabetes mellitus, alcoholism, chronic renal 
failure, malnutrition and infection with the HIV. Pyridoxine 10 mg daily should be given to these at-
risk patients as a prophylaxis.  
 Hypersensitivity reactions, which may occur together: fever, purpura, erythema multiforme. 
 Hepatitis (more common in the over 35-year-olds): patients should be advised to report any nausea, 




 Gastro-intestinal symptoms: anorexia, nausea, vomiting and aggravation of the symptoms of peptic 
ulcer. 
 Hepatitis (see above): this may range from symptomless changes in LFTs to the rare occurrence of liver 
necrosis. 
 Rashes including light sensitivity and urticaria. 
 Arthralgia. 
 Gout: pyrazinamide breaks down to pyrazinoic acid, which inhibits the excretion of uric acid by the 
kidney tubules. 
 Sideroblastic anaemia. 
Ethambutol 
 Ocular toxicity (retrobulbar neuritis) which tends to be dose-related (i.e. the higher the dose the 
greater the chance of this problem). Avoid this drug in patients with impaired renal function otherwise 
serum levels will rise and increase the risk of this eye side-effect. Warn patients to report any changes 
in their vision. 
 Red/green colour blindness. 
 Peripheral neuropathy. 
 Rashes including urticaria and pruritus. 
 Hepatitis (see above). 
 Thrombocytopaenia. 
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Thiacetazone 
 Gastro-intestinal symptoms: anorexia, nausea, vomiting. 
 Skin hypersensitivity including erythema multiforme and exfoliative dermatitis. "Skin rash has been reported 
as a common problem among HIV-positive people receiving thiacetazone. In a retrospective survey, 24/79 (30.4%) 
Zambian HIV-positive adults who were treated with a thiacetazone-containing antituberculous regimen were found to have 
developed a skin rash that required a change of treatment. A cohort study of Zambian children aged between 1 month and 
15 years also reported a high rate of adverse effects among HIV-positive children treated with thiacetazone (19/88 [22%]). 
Twelve children (14%) developed a severe mucocutaneous reaction (Stevens-Johnson syndrome) and 11 (13%) of these 




 Haemolytic anaemia and agranulocytosis (strictly means the absence of polymorphonuclear 
granulocytes). 
 
HIV-infected patients: a special note 
These patients are more likely to experience side-effects from anti-tuberculosis chemotherapy (see 
thiacetazone above). The particular adverse reactions are: 
 Cutaneous. 
 Hypersensitivity reactions. 
 Blood complications. 
 Hepatic toxicity. 
 Rifampicin may cause anaphylaxis. 
 Rifampicin and isoniazid reduce the beneficial effects of ketoconazole and fluconazole. 
 The absorption of rifampicin by the gastro-intestinal tract may be reduced by ketoconazole. 
 
Editor’s note: If any of our readers come across an unusual reaction to a drug (perhaps in association 
with other diseases) please send a case report to this journal. Such experiences can then be widely 
shared amongst colleagues. 
Reference 
1. Antituberculous treatment containing thiacetazone: http://bestpractice.bmj.com/best-
practice/evidence/intervention/0920/0/sr-0920-i3.html  
 
Do you think many medicines are prescribed, dispensed or sold inappropriately in South Sudan? 
If so you may be interested to read about the Rational use of medicines in: 
 WHO Fact Sheet 338 of May 2010 at http://www.who.int/mediacentre/factsheets/fs338/en) and  
 The Lancet, Volume 375, Issue 9731, Page 2052, 12 June 2010. 
 
The XVII International AIDS Conference took place in Vienna in July 2010. News from the conference 
was published in Aidsmap, the publication of NAM. NAM, a UK-based organisation, delivers HIV 
information across the world to HIV-positive people and to the professionals who treat, support and care for 
them. See more details, download their free fact sheets and subscribe to the Aidsmap newsletter at 
www.aidsmap.com. Below are some of the papers given at the Vienna meeting (to find them scroll around 
http://www.aidsmap.com/page/1442063): 
 New drug – rilpivirine does well in trials  
 New drug – experimental integrase inhibitor shows promise  
 HIV and hepatitis C – bone problems more common  
 HIV and children – early treatment cost-effective  
 HIV and tuberculosis – rapid ART saves lives  
 Extended-release nevirapine works well 
 The HIV epidemic and gay men – a mixed picture 
 Microbicides and circumcision  
 Where next for microbicides?  
 Safety of HIV treatment during pregnancy  
 ART in pregnancy: cost-effective and practical approaches being explored  
 New drug – effect on HIV and inflammation 
